Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9743896 | 0.84 | L3MBTL1 (0.73) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL19808153 | 0.81 | L3MBTL1 (0.63) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL13702321 | 0.79 | L3MBTL1 (0.72) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL4005434 | 0.79 | L3MBTL1 (0.61) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL12968364 | 0.79 | L3MBTL1 (0.72) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL15377775 | 0.79 | L3MBTL1 (0.61) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL1923226 | 0.79 | L3MBTL1 (0.61) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL233183 | 0.78 | HSD11B1 (0.58) | EPHX2HSD11B1 | |
| SCHEMBL15224285 | 0.78 | L3MBTL1 (0.59) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 | |
| SCHEMBL1016262 | 0.78 | L3MBTL1 (0.65) | L3MBTL1EPHX2HSD17B10HSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015035234-A2 | ANTI-MICROBIAL COMPOUNDS AND COMPOSITIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-12 | — | — | WO | disclosed |
| US-20140045779-A1 | COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION | XU LIFENG (US) | 2014-02-13 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | AGOURON PHARMACEUTICALS INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1812407-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | Pfizer, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| WO-2006048750-A2 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBSTITUTED ADAMANTYL AMIDES | PFIZER INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-24 | — | — | US | disclosed |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245532-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | L3MBTL1 2687/4885EPHX2 696/4885HSD17B10 11/4885 |
| US-20090093463-A1 | NOVEL COMPOUNDS OF SUBSTITUTED AND UNSUBTITUTED ADAMANTYL AMIDES | HSD11B1, HSD11B2, HSD17B11 | L3MBTL1 4576/4885EPHX2 1942/4885HSD17B10 25/4885 |
| US-20140045779-A1 | COMPOUNDS CONTAINING AN ALICYCLIE STRUCTURE AND ANTI-TUMOR APPLICATION | ALPI, SI, SLC5A11 | L3MBTL1 3387/4885EPHX2 1521/4885HSD17B10 1058/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | L3MBTL1 809/4885EPHX2 3472/4885HSD17B10 498/4885 |
| US-20050245533-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenaseType 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | L3MBTL1 2382/4885EPHX2 676/4885HSD17B10 11/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | L3MBTL1 1085/4885EPHX2 3391/4885HSD17B10 364/4885 |
| US-20050261302-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their therapeutic application | HSD11B1, HSD17B1, HSD3B1 | L3MBTL1 2687/4885EPHX2 696/4885HSD17B10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.